DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer’s disease
Stockholm, November 8, 2021 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by the Washington University School of Medicine in St. Louis, has agreed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to amend the clinical study (Tau NexGen) design to include a background anti-amyloid agent. The Tau NexGen clinical study was originally designed to focus on therapies that target tau. With increasing evidence from clinical studies showing that